STDs

This pamphlet provides information about the STD syphilis. It lists basic facts about the disease and discusses transmission, symptoms for men and women, testing, and treatment. The pamphlet explains that recent sex partners should be notified, as they would need to be tested for the disease and treated if infected. Syphilis can be cured with antibiotic treatment, but an individual can be reinfected.

This report describes tests of an analysis of data from five laboratories that used reverse sequence screening during 2006-2010 to identify persons with possible untreated syphilis. Three sites served patient populations with low prevalence of syphilis, and two sites served patient population with high prevalence. The results indicated that among sera reactive on initial screening with an automatable treponemal enzyme and chemiluminescence immunoassays (EIA/CIA), 56.7 percent had a nonreactive rapid plasma regain (RPR) test.

This report provides a summary of responses from a web-based survey of public health laboratories on volume and type of testing for STDs in the United States in 2007. The survey was conducted in 2008. Responses were received from 61.4 percent (94 of 153) participants. In 2007, 3,290,390 chlamydia tests and 3,157,827 gonorrhea tests were performed in the surveyed laboratories; 89.7 percent of chlamydia tests and 84.4 percent of gonorrhea tests were nucleic acid amplification tests. Over 90 percent of responders reported syphilis testing.

This report summarizes laboratory and epidemiologic findings associated with reduced susceptibility to azithromycin. It notes that in August-October 2009, five of 55 N. gonorrhoeae isolates obtained from men with symptomatic urethritis tested at San Diego County’s main municipal STD clinic had high azithromycin minimum inhibitory concentrations (MIC)s.

The "What is TB?" video provides general information about TB disease and TB infection. The video is available in English, Tagalog, Spanish, and Vietnamese.

On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of quadrivalent human papillomavirus (HPV) vaccine (HPV4; Gardasil, Merck & Co. Inc.) in males aged 11 or 12 years. ACIP also recommended vaccination with HPV4 for males aged 13 through 21 years who have not been vaccinated previously or who have not completed the 3-dose series; males aged 22 through 26 years may be vaccinated. These recommendations replace the October 2009 ACIP guidance that HPV4 may be given to males aged 9 through 26 years.

This report summarizes trends in cephalosporin susceptibility among N. gonorrhoeae isolates in the United States during 2000--2010 using data from the Gonococcal Isolate Surveillance Project (GISP). During that period, the percentage of isolates with elevated minimum inhibitory concentrations (MICs) to cephalosporins (=0.25 µg/mL for cefixime and =0.125 µg/mL for ceftriaxone) increased from 0.2% in 2000 to 1.4% in 2010 for cefixime and from 0.1% in 2000 to 0.3% in 2010 for ceftriaxone.

This report examines existing sexually transmitted disease (STD) screening programs in large jails to learn lessons that can benefit other health departments that want to establish or expand chlamydia (CT) and gonorrhea (GC) screening programs in their local jails. It provides key findings and recommendations for implementing and/or expanding jail STD screening programs. The appendices give summaries of each jail vist and contact information is also provided from each jail visit.

This Toolkit is the principal outcome of the second phase of the EPT law project. It is intended as a resource for voluntary use by government officials at the state and local levels, their public and private sector partners, and others who are interested in adopting or facilitating the implementation of statutes or regulations that permit EPT in clinical practice. This Toolkit is not designed to provide specific legal guidance or advice and does not represent the official legal positions of federal, state, or local governments.

This pamphlet provides the general public with information on genital warts. The pamphlet discusses various types of warts, transmission, symptoms, medical treatment, and the relationship of warts to cancer. Contact information is provided for sexual health services in Australia.